Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Omnicom Group Inc. — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.81 (market cap $8.88B), while Omnicom Group Inc. trades at $78.98 (market cap $21.51B). The key difference: Omnicom Group Inc. is far larger — about 2.4× Kymera Therapeutics Inc. Common Stock's market cap, and Omnicom Group Inc. pays a 4.08% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Omnicom Group Inc. for 64 Days on average.
| KYMR | OMC | |
|---|---|---|
Market Cap | $8.88B | $21.51B |
Volume | 1,028,790 | 2,093,740 |
Sector | Health | Media |
52-Week High | $127.31 | $88.94 |
52-Week Low | $55.80 | $67.27 |
Typical Hold Time | 0 Days | 64 Days |
Enterprise Value | $8.27B | $29.59B |
Dividend Yield | — | 4.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Omnicom Group (OMC) trades at $78.49, up 1.84% with a bullish technical signal despite mixed earnings results. The stock shows strong cash flow generation ($2.54B net in 2025) and maintains leadership recognition in marketing services. Valuation metrics present a mixed picture with a high P/E ratio of 212.14 but attractive P/S of 0.88, while recent earnings show two misses and one beat in the last four quarters.
OMC offers value with a consensus price target of $100.50 (28% upside) and a 4.2% dividend yield, though investors face risks from advertising market volatility and elevated debt levels. The company's scale advantages and AI capabilities provide growth catalysts, but margin pressure and competitive threats require monitoring for sustained performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
